Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

24.25 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
This Cathie Wood Stock Is Down 40% in 2023. Here's Why She's Still Buying It.
The decline of Beam's stock says little about its long-term potential, according to Wood. 
Via The Motley Fool
Cathie Wood's Buying These 3 Stocks Hand Over Fist
A drugmaker, a gene sequencer, and a streaming business all made deep impressions on Ark Invest's stock-picking team. 
Via The Motley Fool
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
First Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease Models 
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Invest Keeps Shedding Shopify Nvidia Shares, Loads Up On Spotify Stock
 
Via Benzinga
4 Analysts Have This to Say About Beam Therapeutics
 
Via Benzinga
2 Supercharged Growth Stocks That Could Make You Richer
These two companies could disrupt healthcare on a global scale. 
Via The Motley Fool
Beam Therapeutics' Role In Gene-Editing 2.0 Revolution: First U.S. Patient Treated With Base-Edited Cell Therapy
Beam Therapeutics Inc (NASDAQ: BEAM) announced that in August, the first patient was treated with BEAM-201, a quadruplex-edited allogeneic  
Via Benzinga
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States 
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in Upcoming September Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Why Is Apellis Pharmaceuticals Stock Trading Lower Today?
Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) and  
Via Benzinga
Beam Therapeutics: Q1 Earnings Insights
 
Via Benzinga
3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street
These cutting-edge biotech stocks could deliver life-changing gains for early shareholders. 
Via The Motley Fool
Got $200? 3 Growth Stocks to Buy That Could Double Your Money
There's no guarantee that any stock will deliver 2 times returns. But the chances for these stocks look pretty good. 
Via The Motley Fool
Cathie Wood's Ark Invest Sells More Tesla Stock — Acquires Shares Of Flying Taxi Company
 
Via Benzinga
Cathie Wood's Ark Invest Sells $2.15M Of Tesla Shares Despite Own Bullish Projections
 
Via Benzinga
Credit Suisse Maintains Neutral Rating for Beam Therapeutics: Here's What You Need To Know
 
Via Benzinga
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
3 Pharma Stocks That AI is Loving in July
Artificial intelligence recommends that these are the three stocks to consider when investing in pharma stocks. 
Via InvestorPlace
Verve Therapeutics Gains 20.74% In June as Ark Funds Invest
Verve Therapeutics' efforts to eliminate cardiovascular disease through gene-editing treatments have momentum, as the stock gets a 20.74% boost in June. 
Via MarketBeat
Here's the Secret Behind Cathie Wood's Latest Moneymaking Strategy
Success could be in the DNA of the Ark Invest founder. 
Via The Motley Fool
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
It's facing a few issues that are practically guaranteed to affect shareholder returns. 
Via The Motley Fool
Beam Therapeutics to Participate in Upcoming May Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?
The Ark Invest CEO is betting on rebounds for these beaten-down stocks. 
Via The Motley Fool
Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
7 Best Cathie Wood Stocks for Your May 2023 Buy List
This year promises to be very different for Cathie Wood stocks, as signs of economic improvement become more prominent. 
Via InvestorPlace
3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers
Cathie Wood is loading up on these biotech stocks. 
Via The Motley Fool
The 3 Most Promising Gene Editing Stocks to Buy in 2023
Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in. 
Via InvestorPlace
Cathie Wood Is Unstoppable With Tesla Stock – Defies Wall Street To Make Whopping $29M Purchase
 
Via Benzinga
3 Stocks to Watch in April: Is it Time to Buy?
With several fundamental factors pushing against the equities sector, these stocks to watch in particular draw significant intrigue. 
Via InvestorPlace
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.